A detailed history of Congress Asset Management CO transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Congress Asset Management CO holds 1,032,141 shares of SUPN stock, worth $27.1 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
1,032,141
Previous 920,808 12.09%
Holding current value
$27.1 Million
Previous $26.6 Million 32.11%
% of portfolio
0.26%
Previous 0.22%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 11, 2024

BUY
$27.11 - $35.17 $3.02 Million - $3.92 Million
111,333 Added 12.09%
1,032,141 $35.2 Million
Q4 2023

Mar 04, 2024

BUY
$22.72 - $29.68 $82,791 - $108,153
3,644 Added 0.4%
920,808 $26.6 Million
Q3 2023

Nov 01, 2023

BUY
$27.57 - $32.91 $4.06 Million - $4.84 Million
147,105 Added 19.1%
917,164 $25.3 Million
Q2 2023

Jul 27, 2023

BUY
$29.91 - $38.73 $6.26 Million - $8.11 Million
209,422 Added 37.35%
770,059 $23.1 Million
Q1 2023

Apr 21, 2023

BUY
$34.93 - $42.03 $1.88 Million - $2.26 Million
53,846 Added 10.62%
560,637 $20.3 Million
Q4 2022

Jan 18, 2023

SELL
$31.09 - $37.88 $20,892 - $25,455
-672 Reduced 0.13%
506,791 $0
Q3 2022

Nov 08, 2022

BUY
$28.79 - $35.41 $746,265 - $917,862
25,921 Added 5.38%
507,463 $17.2 Million
Q2 2022

Aug 02, 2022

BUY
$25.33 - $34.25 $441,780 - $597,354
17,441 Added 3.76%
481,542 $13.9 Million
Q1 2022

Apr 20, 2022

BUY
$28.51 - $32.9 $1.94 Million - $2.24 Million
67,996 Added 17.17%
464,101 $15 Million
Q4 2021

Jan 28, 2022

BUY
$26.37 - $34.22 $2.17 Million - $2.81 Million
82,250 Added 26.21%
396,105 $11.6 Million
Q3 2021

Nov 08, 2021

BUY
$23.54 - $31.39 $449,001 - $598,732
19,074 Added 6.47%
313,855 $8.37 Million
Q2 2021

Aug 05, 2021

BUY
$26.72 - $33.19 $7.88 Million - $9.78 Million
294,781 New
294,781 $9.08 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.4B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Congress Asset Management CO Portfolio

Follow Congress Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Congress Asset Management CO , based on Form 13F filings with the SEC.

News

Stay updated on Congress Asset Management CO with notifications on news.